CAPR
Capricor Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow -7.1% ·
net new positions +9.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | -1 | 21.29M | $513.07M | +4 | −5 |
| Q1 2026 | 74 | +11 | 17.90M | $543.13M | +17 | −6 |
| Q4 2025 | 63 | 0 | 16.01M | $462.15M | +1 | −1 |
| Q3 2025 | 17 | +3 | 9.08M | $65.46M | +3 | — |
| Q2 2025 | 11 | +1 | 8.31M | $82.57M | +2 | −1 |
| Q1 2025 | 7 | -3 | 3.63M | $34.48M | — | −3 |
| Q4 2024 | 10 | +4 | 3.77M | $51.99M | +5 | −1 |
| Q3 2024 | 5 | -1 | 1.06M | $16.12M | +2 | −3 |
| Q2 2024 | 6 | — | 1.44M | $6.86M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 2.98M | — | $29.63M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 2.31M | — | $22.89M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 2.31M | — | $22.89M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 2.31M | — | $22.89M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passive) | 2.31M | — | $22.89M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passive) | 2.31M | — | $22.89M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | State Street Global Advisors ✦ (passive) | 1.47M | -20.4% | $14.56M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Geode Capital Management ✦ (passive) | 963.08K | +6.8% | $9.56M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passive) | 963.08K | +6.8% | $9.56M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 19 | Millennium Management ✦ | 173.85K | -21.7% | $1.73M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 155.84K | +24.7% | $1.55M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 21 | Wellington Management ✦ | 131.88K | +19.1% | $1.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 22 | Wellington Management ✦ | 131.88K | +19.1% | $1.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 23 | Wellington Management ✦ | 131.88K | +19.1% | $1.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 24 | Marshall Wace ✦ | 80.19K | New | $796,257 | 0.0% | New | 1 | SEC ↗ |
| 25 | Marshall Wace ✦ | 80.19K | New | $796,257 | 0.0% | New | 1 | SEC ↗ |
| 26 | Fidelity (FMR) ✦ | 24.19K | — | $240,206 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Fidelity (FMR) ✦ | 24.19K | — | $240,206 | 0.0% | n/c | 1 | SEC ↗ |
| 28 | T. Rowe Price ✦ | 19.02K | +22.5% | $189,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 29 | D. E. Shaw & Co. ✦ | 10.73K | New | $106,579 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $796,257 | 0.0% |
| Marshall Wace | $796,257 | 0.0% |
| D. E. Shaw & Co. | $106,579 | 0.0% |
Exited
| Citadel Advisors | $3.95M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 176 holders, 33.48M shares, $1.02B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.